Cuba for mass anti-covid-19 vaccination.

Havana, Sep 21 (RHC) A total of 18 million 402 thousand 491 doses of immunogens against the SARS-CoV-2 virus, which causes Covid-19, were administered in Cuba, reported the Ministry of Public Health.

According to the Ministry's website, 8,377,546 people received one dose of the Cuban immunizers, while 5,445,423 have already received the second dose and 4,568,48 the third.

Cuba has three anti-Covid-19 schemes that exceed the limit imposed by the World Health Organization (50 percent) to be declared vaccines and one of these, Abdala, has already been authorized for emergency use in the country, as has Soberana 02 for the pediatric population.

Abdala, designed by the Center for Genetic Engineering and Biotechnology (CIGB), the first vaccine in Latin America, showed 92.28 percent efficacy in its three-injection schedule.

In addition, the vaccine of the Finlay Vaccine Institute (IFV) Soberana 02, with two injections, showed 65.6 percent efficacy on symptomatic disease in its final analysis, a figure that increased after the 62 percent reported in the intermediate study.

The IFV also announced the 91.2 percent efficacy of the two-dose schedule of Soberana 02 plus one dose of Soberana Plus vaccine.

In addition to the above mentioned Cuban immunogens, there are the candidates Mambisa, also from CIGB and unique for nasal application, which obtained permission from the local health authorities to start Phase II clinical trials; and Soberana 01, from IFV. (Source: Prensa Latina)